Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Strategic Apoptosis Detection: From Mechanism to Translation
2026-07-15
This article examines the mechanistic and translational landscape of apoptosis detection, spotlighting the One-step TUNEL Cy3 Apoptosis Detection Kit. Integrating insights from recent advances in cell death research and highlighting competitive, workflow, and validation considerations, the piece offers actionable guidance to translational researchers seeking robust, quantitative DNA fragmentation assays. The discussion explicitly connects emerging evidence on cell death modalities in oncology—including apoptosis and pyroptosis—and positions APExBIO’s validated solution as a benchmark for sensitive and reproducible detection in complex biological models.
-
Morin: Beyond Mitochondrial Modulation—A Systems Biology Per
2026-07-15
Explore the multifaceted roles of Morin, a natural flavonoid, as a mitochondrial modulator and fluorescent probe. This article uniquely integrates systems-level insights into Morin’s mechanisms, highlighting its value for advanced disease modeling and research.
-
Dose-Dependent PDCoV Infection: Immune Activation and Molecu
2026-07-14
This study reveals how the infectious dose of porcine deltacoronavirus (PDCoV) determines the scale and nature of host immune responses, with high doses inducing excessive inflammation and low doses primarily activating antiviral pathways. These mechanistic findings clarify the role of STAT1 and its downstream interferon-stimulated genes (ISG15, MX2) in controlling PDCoV, informing targeted approaches for immunomodulation in swine disease models.
-
Targeting ERα DBD-LBD Interface: Mitoxantrone's Novel Mechan
2026-07-14
Wang et al. identify mitoxantrone as an allosteric inhibitor of estrogen receptor alpha (ERα), disrupting its function by binding to the DBD-LBD interface and inducing rapid proteasomal degradation. This mechanistic advance overcomes resistance mutations in luminal breast cancer and establishes a new paradigm for nuclear receptor targeting.
-
Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Angi
2026-07-13
This study establishes anlotinib hydrochloride as a highly potent and selective inhibitor of VEGFR2, demonstrating superior anti-angiogenic activity and tumor growth suppression in preclinical models. The findings clarify mechanistic and selectivity advantages over earlier tyrosine kinase inhibitors and inform experimental design for cancer and angiogenesis research.
-
MDM1 Overexpression Enhances Apoptosis and Therapy Response
2026-07-13
This study uncovers how MDM1 overexpression in colorectal cancer (CRC) promotes p53 expression and apoptosis, leading to improved chemoradiotherapy sensitivity. The findings establish MDM1 as both a mechanistic biomarker and a potential target for overcoming therapeutic resistance in CRC.
-
SOAT1 Inhibition Restores Lipophagy in PHMG-Induced Lung Fib
2026-07-12
This study identifies sterol O-acyltransferase 1 (SOAT1) as a key mediator of foam cell formation and lipid dysregulation in PHMG-induced pulmonary fibrosis, showing that SOAT1 inhibition restores macrophage lipophagy and reduces fibrotic progression. These findings provide a mechanistic basis for targeting SOAT1 in the treatment of environmentally triggered lung fibrosis.
-
11β-HSD1 Inhibition Reduces Liver Fibrosis via Notch and NK
2026-07-10
A recent study demonstrates that selective inhibition of 11β-HSD1 significantly reduces liver fibrosis by suppressing the Notch signaling pathway and enhancing natural killer (NK) cell-mediated clearance of hepatic stellate cells. These findings provide mechanistic insight into immunometabolic regulation in metabolic dysfunction-associated steatotic liver disease (MASLD) and highlight new anti-fibrotic therapeutic targets.
-
GRA12: A Broad-Spectrum Virulence Factor in Toxoplasma gondi
2026-07-09
This study systematically identified GRA12 as a conserved, secreted virulence factor critical for Toxoplasma gondii survival across diverse parasite strains and mouse subspecies. The findings deepen our mechanistic understanding of host-pathogen interactions and provide a refined platform for dissecting immune evasion in apicomplexan parasites.
-
Bufuralol Hydrochloride in β-Adrenergic Modulation Workflows
2026-07-09
Bufuralol hydrochloride empowers researchers to interrogate human β-adrenergic signaling with unprecedented fidelity using advanced hiPSC-derived intestinal organoid systems. Its partial agonist activity and robust membrane-stabilizing effects make it uniquely suited for translational cardiovascular pharmacology and drug metabolism studies.
-
Annexin V: Strategic Advances in Apoptosis and Immune Tolera
2026-07-08
This thought-leadership article, authored by APExBIO’s scientific marketing team, explores the evolving landscape of Annexin V applications in cell death and immune tolerance research. Blending mechanistic insights with actionable guidance for translational investigators, we connect the latest mechanistic findings—such as miR-519d-3p’s role in preeclampsia—with the strategic deployment of recombinant Annexin V as a precision tool for apoptosis assay design and immune modulation studies. We review the competitive landscape, protocol best practices, and emerging translational frontiers, providing mature, evidence-driven recommendations for researchers seeking to bridge fundamental discoveries with clinical impact.
-
PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Advance
2026-07-08
PYR-41, the selective inhibitor of Ubiquitin-Activating Enzyme E1 from APExBIO, empowers researchers to dissect protein degradation and immune signaling with unprecedented precision. This guide delivers practical protocols, troubleshooting strategies, and actionable insights for leveraging PYR-41 in translational inflammation and viral immunity models.
-
Hydrocortisone in Inflammation and Stemness Models: Protocol
2026-07-07
Hydrocortisone from APExBIO empowers researchers to dissect glucocorticoid hormone effects in inflammation, stress response, and cancer stemness models with precision. This article delivers workflow upgrades, protocol optimizations, and troubleshooting intelligence — especially for multidimensional tumor microenvironment studies.
-
A-1210477: Optimizing MCL-1 Inhibitor Workflows in Cancer Re
2026-07-07
A-1210477, a potent MCL-1 inhibitor, allows researchers to dissect MCL-1-dependent apoptosis with unmatched specificity. This article delivers actionable workflow upgrades, troubleshooting advice, and comparative insights to boost reproducibility and mechanistic clarity in cancer cell survival studies.
-
Bufuralol Hydrochloride in iPSC Organoids for Cardiovascular
2026-07-06
Bufuralol hydrochloride unlocks more human-relevant, reproducible pharmacokinetic and β-adrenergic modulation studies by integrating seamlessly into iPSC-derived intestinal organoid platforms. This article delivers practical, protocol-level guidance and troubleshooting strategies that set your cardiovascular pharmacology assays apart.